121 related articles for article (PubMed ID: 30937725)
1. Early-age Ndufs4 knockout mice are an inappropriate animal model of Leigh syndrome.
Finsterer J
Radiol Phys Technol; 2019 Jun; 12(2):230-231. PubMed ID: 30937725
[No Abstract] [Full Text] [Related]
2. Detection of increased intracerebral lactate in a mouse model of Leigh syndrome using proton MR spectroscopy.
Takahashi Y; Kioka H; Shintani Y; Ohki A; Takashima S; Sakata Y; Higuchi T; Saito S
Magn Reson Imaging; 2019 May; 58():38-43. PubMed ID: 30668983
[TBL] [Abstract][Full Text] [Related]
3. Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention.
van de Wal MAE; Adjobo-Hermans MJW; Keijer J; Schirris TJJ; Homberg JR; Wieckowski MR; Grefte S; van Schothorst EM; van Karnebeek C; Quintana A; Koopman WJH
Brain; 2022 Mar; 145(1):45-63. PubMed ID: 34849584
[TBL] [Abstract][Full Text] [Related]
4. Regional metabolic signatures in the Ndufs4(KO) mouse brain implicate defective glutamate/α-ketoglutarate metabolism in mitochondrial disease.
Johnson SC; Kayser EB; Bornstein R; Stokes J; Bitto A; Park KY; Pan A; Sun G; Raftery D; Kaeberlein M; Sedensky MM; Morgan PG
Mol Genet Metab; 2020 Jun; 130(2):118-132. PubMed ID: 32331968
[TBL] [Abstract][Full Text] [Related]
5. The NDUFS4 Knockout Mouse: A Dual Threat Model of Childhood Mitochondrial Disease and Normative Aging.
Grillo AS; Bitto A; Kaeberlein M
Methods Mol Biol; 2021; 2277():143-155. PubMed ID: 34080150
[TBL] [Abstract][Full Text] [Related]
6. Early detection of elevated lactate levels in a mitochondrial disease model using chemical exchange saturation transfer (CEST) and magnetic resonance spectroscopy (MRS) with 7T MR imaging.
Saito S; Takahashi Y; Ohki A; Shintani Y; Higuchi T
Radiol Phys Technol; 2019 Jun; 12(2):232-233. PubMed ID: 30937724
[No Abstract] [Full Text] [Related]
7. Microglial response promotes neurodegeneration in the Ndufs4 KO mouse model of Leigh syndrome.
Aguilar K; Comes G; Canal C; Quintana A; Sanz E; Hidalgo J
Glia; 2022 Nov; 70(11):2032-2044. PubMed ID: 35770802
[TBL] [Abstract][Full Text] [Related]
8. Iron status influences mitochondrial disease progression in Complex I-deficient mice.
Kelly CJ; Couch RK; Ha VT; Bodart CM; Wu J; Huff S; Herrel NT; Kim HD; Zimmermann AO; Shattuck J; Pan YC; Kaeberlein M; Grillo AS
Elife; 2023 Feb; 12():. PubMed ID: 36799301
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics of Ndufs4
Terburgh K; Lindeque Z; Mason S; van der Westhuizen F; Louw R
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):98-106. PubMed ID: 30391276
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia ameliorates brain hyperoxia and NAD
Grange RMH; Sharma R; Shah H; Reinstadler B; Goldberger O; Cooper MK; Nakagawa A; Miyazaki Y; Hindle AG; Batten AJ; Wojtkiewicz GR; Schleifer G; Bagchi A; Marutani E; Malhotra R; Bloch DB; Ichinose F; Mootha VK; Zapol WM
Mol Genet Metab; 2021 May; 133(1):83-93. PubMed ID: 33752971
[TBL] [Abstract][Full Text] [Related]
11. Succination is Increased on Select Proteins in the Brainstem of the NADH dehydrogenase (ubiquinone) Fe-S protein 4 (Ndufs4) Knockout Mouse, a Model of Leigh Syndrome.
Piroli GG; Manuel AM; Clapper AC; Walla MD; Baatz JE; Palmiter RD; Quintana A; Frizzell N
Mol Cell Proteomics; 2016 Feb; 15(2):445-61. PubMed ID: 26450614
[TBL] [Abstract][Full Text] [Related]
12. Gait analysis in a mouse model resembling Leigh disease.
de Haas R; Russel FG; Smeitink JA
Behav Brain Res; 2016 Jan; 296():191-198. PubMed ID: 26363424
[TBL] [Abstract][Full Text] [Related]
13. Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy.
Manning A; Han V; Stephens A; Wang R; Bush N; Bard M; Ramirez JM; Kalume F
Neurobiol Dis; 2023 Oct; 187():106288. PubMed ID: 37704057
[TBL] [Abstract][Full Text] [Related]
14. Fatal breathing dysfunction in a mouse model of Leigh syndrome.
Quintana A; Zanella S; Koch H; Kruse SE; Lee D; Ramirez JM; Palmiter RD
J Clin Invest; 2012 Jul; 122(7):2359-68. PubMed ID: 22653057
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma contributes to disease progression in the Ndufs4(-/-) model of Leigh syndrome.
Hanaford AR; Khanna A; James K; Truong V; Liao R; Chen Y; Mulholland M; Kayser EB; Watanabe K; Hsieh ES; Sedensky M; Morgan PG; Kalia V; Sarkar S; Johnson SC
Neuropathol Appl Neurobiol; 2024 Jun; 50(3):e12977. PubMed ID: 38680020
[TBL] [Abstract][Full Text] [Related]
16. Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh syndrome.
Bitto A; Grillo AS; Ito TK; Stanaway IB; Nguyen BMG; Ying K; Tung H; Smith K; Tran N; Velikanje G; Urfer SR; Snyder JM; Barton J; Sharma A; Kayser EB; Wang L; Smith DL; Thompson JW; DuBois L; DePaolo W; Kaeberlein M
Nat Metab; 2023 Jun; 5(6):955-967. PubMed ID: 37365290
[TBL] [Abstract][Full Text] [Related]
17. Double administration of self-complementary AAV9NDUFS4 prevents Leigh disease in Ndufs4-/- mice.
Corrà S; Cerutti R; Balmaceda V; Viscomi C; Zeviani M
Brain; 2022 Oct; 145(10):3405-3414. PubMed ID: 36270002
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease.
de Haas R; Das D; Garanto A; Renkema HG; Greupink R; van den Broek P; Pertijs J; Collin RWJ; Willems P; Beyrath J; Heerschap A; Russel FG; Smeitink JA
Sci Rep; 2017 Sep; 7(1):11733. PubMed ID: 28916769
[TBL] [Abstract][Full Text] [Related]
19. Targeting NAD
Lee CF; Caudal A; Abell L; Nagana Gowda GA; Tian R
Sci Rep; 2019 Feb; 9(1):3073. PubMed ID: 30816177
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.
Johnson SC; Yanos ME; Kayser EB; Quintana A; Sangesland M; Castanza A; Uhde L; Hui J; Wall VZ; Gagnidze A; Oh K; Wasko BM; Ramos FJ; Palmiter RD; Rabinovitch PS; Morgan PG; Sedensky MM; Kaeberlein M
Science; 2013 Dec; 342(6165):1524-8. PubMed ID: 24231806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
